Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…
Lead author of JAMA article rethinks positive Zoloft report – Guardian Wed, 1 Oct 2003 In August 2003, the Sertraline Pediatric Study Group reported: “Sertraline-treated patients experienced statistically significantly greater improvement than placebo.” Their report was published in the authoritative Journal of the American Medical Association (JAMA). The authors claimed…
Prozac Revisited: Concerns About Suicides Surface – Boston Globe Eli Lilly’s denial about the risk of suicide for some patients prescribed Prozac was the subject of a series of reports in the Boston Globe. The article (Sunday, June 11) revealed the irony behind the duplicity. Dr. Martin Teicher, who first…
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
No legitimate physician would use the physician’s professional license to help repressive government regimes intimidate dissidents.
Pharmaceutical industry corrupt practices are in evidence again, and again, and again.
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”
Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ).
"Drug companies should not be allowed to evaluate their own products."
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.
